The San Diego, Calif.-based company said the portfolio will support multiple approaches to spinal fixation procedures, including open, maximum access surgery or hybrid approaches.
NuVasive claims that its portfolio of products will allow surgeons to transition from open to MAS spinal procedures, and to customize implant types and support a number of different techniques.
“The versatility of the new Reline Trauma system allows me to address trauma surgery circumferentially. NuVasive has removed the need for a second surgeon and eliminated hours in comparison to the alternative technique. Reline Trauma is a game-changer in spine,” Dr. Juan Uribe of Tampa, Fla.’s University of South Florida College of Medicine said in a prepared release.
The platform will also allow for controlled, dialed-in fracture correction through a dual rack system, with or without a rod present in the construct, the company said.
“The launch of Reline Trauma is a key milestone in our continued commitment to industry-leading innovation that delivers untapped clinical and economic value for our surgeon partners. Reline Trauma will help define the standard of trauma care for spine, with its ability to dramatically reduce time and provide complete versatility intra-operatively. The system will be the foundation of our trauma portfolio as we invest further in this key market,” prez & CEO Jason Hannon said in a press release.
In March, NuVasive said it won FDA 510(k) clearance for its CoRoent small interbody implant for fusion procedures in the cervical spine, claiming it as the 1st U.S. nod for a cervical cage used at up to 4 levels.
The CoRoent device is an interbody cage made of PEEK-Optima polymer, designed to stabilize the cervical spinal during fusion. It’s hollow to allow autogenous and/or allogeneic bone grafts to be inserted. The FDA clearance covers the CoRoent small, small lordotic, small lordotic plus, small hyperlordotic and small contoured implants, NuVasive said.